In bladder cancer, Apigenin inhibited the proliferation of T24 cells, blocking cell cycle progression at the G2/M checkpoint through an increase in p21 and p27 protein levels and a decrease in Cyclin A, Cyclin B1, Cyclin E, cyclin-dependent kinase-2 (CDK2), Cdc2, and Cdc25C levels [101]. This evidence concerns the gene CDK2 and urinary bladder cancer.